AFA
ALNY icon

Abacus FCF Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Abacus FCF Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-22,023
Closed -$1.77M – 102
2015
Q3 		$1.77M Buy
+22,023
New +$2.45M 0.91% 92

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Abacus FCF Advisors's ALNY Position: Q4 2015 in Review

Abacus FCF Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 22,023 shares — an estimated $1.77M sold.

Abacus FCF Advisors first reported a position in ALNY in Q3 2015 and held it in 1 quarter. The position peaked at $1.77M in Q3 2015. 260 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

  • Abacus FCF Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Abacus FCF Advisors sold 22,023 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $1.77M.
  • Abacus FCF Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Abacus FCF Advisors's Alnylam Pharmaceuticals position peaked at $1.77M in Q3 2015.
  • 260 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on Abacus FCF Advisors's 13F filing for Q4 2015, filed 11 Feb 2016.